Ruben J. Boado

Fondatore presso ArmaGen, Inc.

Consumer Services

Health Services

Profilo

Ruben J.
Boado is the founder of ArmaGen, Inc. which was founded in 2004.
He held the title of Vice President-Research & Development.
Dr. Boado's former job was as a Professor at the University of California, Los Angeles.
Dr. Boado received a doctorate degree from Universidad de Buenos Aires.

Posizioni attive di Ruben J. Boado

Società	Posizione	Inizio
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Fondatore	01/01/2004

Tutte le posizioni attive di Ruben J. Boado

Precedenti posizioni note di Ruben J. Boado

Società	Posizione	Fine
University of California, Los Angeles	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Ruben J. Boado

Formazione di Ruben J. Boado

Universidad de Buenos Aires

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ruben J. Boado

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Health Services